Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma

Morihiro Okada, MD, PhD,^a Haruhiko Nakayama, MD, PhD,^b Sakae Okumura, MD, PhD,^c Hiromitsu Daisaki, PhD,^d Shuji Adachi, MD, PhD,^e Masahiro Yoshimura, MD, PhD,^f and Yoshihiro Miyata, MD, PhD^a

Objective: The detection rates of small lung cancers, especially adenocarcinoma, have recently increased. An understanding of malignant aggressiveness is critical for the selection of suitable therapeutic strategies, such as sublobar resection. The objective of this study was to examine the malignant biological behavior of clinical stage IA adenocarcinoma and to select therapeutic strategies using high-resolution computed tomography, fluorodeoxyglucose-positron emission tomography/computed tomography, and a pathologic analysis in the setting of a multicenter study.

Methods: We performed high-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography in 502 patients with clinical T1N0M0 adenocarcinoma before they underwent surgery with curative intent. We evaluated the relationships between clinicopathologic characteristics and maximum standardized uptake values on fluorodeoxyglucose-positron emission tomography/computed tomography, ground-glass opacity ratio, and tumor disappearance rate on high-resolution computed tomography and component of bronchioloalveolar carcinoma on surgical specimens, as well as between these and surgical findings. We used a phantom study to correct the serious limitation of any multi-institution study using positron emission tomography/computed tomography, namely, a discrepancy in maximum standardized uptake values among institutions.

Results: Analyses of receiver operating characteristic curves identified an optimal cutoff value to predict high-grade malignancy of 2.5 for revised maximum standardized uptake values, 20% for ground-glass opacity ratio, 30% for tumor disappearance rate, and 30% for bronchioloalveolar carcinoma ratio. Maximum standardized uptake values and bronchioloalveolar carcinoma ratio, tumor disappearance rate, and ground-glass opacity ratio mirrored the pathologic aggressiveness of tumor malignancy, nodal metastasis, recurrence, and prognosis, including disease-free and overall survival.

Conclusions: Maximum standardized uptake value is a significant preoperative predictor for surgical outcomes. High-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography findings are important to determine the appropriateness of sublobar resection for treating clinical stage IA adenocarcinoma of the lung. (*J Thorac Cardiovasc Surg* 2011;141:1384-91)

Earn CME credits at
<http://cme.ctsnetjournals.org>

From the Department of Surgical Oncology,^a Hiroshima University, Hiroshima, Japan; Department of Thoracic Surgery,^b Kanagawa Cancer Center, Yokohama, Japan; Department of Thoracic Surgery,^c Cancer Institute Hospital, Tokyo, Japan; Department of Radiology,^d National Cancer Center, Tokyo, Japan; and Department of Radiology^e and Thoracic Surgery,^f Hyogo Cancer Center, Akashi, Japan.

Disclosures: Authors have nothing to disclose with regard to commercial support.

Received for publication Nov 26, 2010; revisions received Jan 21, 2011; accepted for publication Feb 9, 2011; available ahead of print March 28, 2011.

Address for reprints: Morihiro Okada, MD, PhD, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima City, Hiroshima 734-0037, Japan (E-mail: morihiro@hiroshima-u.ac.jp).

0022-5223/\$36.00

Copyright © 2011 by The American Association for Thoracic Surgery

doi:10.1016/j.jtcvs.2011.02.007

The standard treatment for operable non-small cell lung cancer, even early clinical T1N0M0 disease, remains lobectomy with dissection of the hilar and mediastinal lymph nodes.¹ However, clinical investigations to date have demonstrated that sublobar resection, which chiefly consists of radical segmentectomy with nodal dissection, might be feasible for treating early lung cancers with the tangible advantages of maintained lung function and a reasonable prognosis.^{2,3} To date, there are no means to preoperatively identify early lung cancers that are biologically less aggressive and may be better suited for a sublobar resection.

Recent advances in high-resolution computed tomography (HRCT) and the widespread application of computed tomography (CT) screening have enhanced the discovery of small lung cancers, particularly adenocarcinoma.^{2,3} These early-stage cancers are biologically heterogeneous, and the malignant aggressiveness is not well characterized

Abbreviations and Acronyms	
AUC	= area under the curve
BAC	= bronchioloalveolar carcinoma
CT	= computed tomography
DFS	= disease-free survival
FDG	= F-18 fluorodeoxyglucose
FOV	= field of view
GGO	= ground-glass opacity
HRCT	= high-resolution computed tomography
maxSUV	= maximum standardized uptake value
PET	= positron emission tomography
ROC	= receiver operating characteristic
SUV	= standardized uptake value
TDR	= tumor disappearance rate

at the time of diagnosis. This information should be considered in selecting the therapeutic strategy.

Positron emission tomography (PET)/CT with F-18 fluorodeoxyglucose (FDG) has become an integral part of the non-small cell lung cancer evaluation.⁴⁻⁶ This modality generates quantitative images based on glucose metabolism reflecting the metabolic activity and proliferative potential of malignant tumors, and providing anatomic CT images. Small-scale studies have demonstrated the role of FDG-PET/CT in assessing the biological status of cancers,^{7,8} but this requires confirmation in a larger cohort. Therefore, assessed the biological nature of small adenocarcinomas in more than 500 patients by using HRCT and FDG-PET/CT and the pathologic findings of surgical specimens in a multicenter setting. Because of the heterogeneity of PET techniques and performance, we corrected inter-institutional errors in maximum standardized uptake values (maxSUVs) resulting from PET/CT scanners of variable quality based on outcomes of a study using an anthropomorphic body phantom that conformed to National Electrical Manufacturers Association standards.⁹

PATIENTS AND METHODS

We enrolled 502 patients (female, 279 [56%]; male, 223 [44%]; mean age, 65.3 ± 9.6 years) with clinical T1N0M0 stage IA adenocarcinoma of the lung at 4 institutions between August 1, 2005, and December 31, 2009. All patients underwent HRCT and FDG-PET/CT followed by curative R0 resection. The ethics committees at each institution approved this multicenter study and the prospective database used in the analysis.

High-Resolution Computed Tomography

Chest images were obtained using 16-row multidetector CT independently of subsequent PET/CT examinations. High-resolution images of the tumors were acquired using the following parameters: 120 kVp, 200 mA, 1- to 2-mm section thickness, 512 × 512 pixel resolution, 0.5- to 1-second scanning time, a high spatial reconstruction algorithm with a 20-cm field of view (FOV) and mediastinal (level, 40 HU; width, 400

FIGURE 1. maxSUV adjusted using experimental phantom (revised max-SUV). Original maxSUV data were calibrated by multiplying calibration factors based on phantom studies to correct inter-institutional SUV variability. MaxSUV ratio is expressed as maxSUV of each institute for max-SUV of control institute (Institute 1). *maxSUV*, Maximum standardized uptake value.

HU) and lung (level, -600 HU; width, 1600 HU) window settings. Ground-glass opacity (GGO) was defined as a misty increase in lung attenuation without obscuring the underlying vascular markings, and we defined the GGO ratio (%) as [1- (maximum dimension of consolidation of lung windows/maximum dimension of tumor of lung windows)] × 100. Tumor disappearance rate (TDR) (%) was defined as [1- (tumor area of the mediastinal windows/tumor area of the lung windows)] × 100.^{2,3,10}

Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography

The patients fasted for more than 4 hours before being intravenously injected with 74-370 MBq of FDG, and then relaxed for at least 1 hour before FDG-PET/CT scanning. Blood glucose was calculated before tracer injection to confirm a level of less than 150 mg/dL.¹¹ Patients with blood glucose values of 150 mg/dL or greater were excluded from PET/CT acquisition. Images were obtained in this study using Discovery ST (GE Healthcare, Buckinghamshire, England), Aquiduo (Toshiba Medical Systems Corporation, Tochigi, Japan), or Biograph Sensation16 (Siemens Healthcare, South Iselin, NJ) integrated PET/CT scanners. Low-dose unenhanced CT images of a 2- to 4-mm section thickness for attenuation correction and localization of lesions identified by PET were obtained from the head to the pelvic floor of each patient using a standard protocol. Immediately after CT, PET covered the identical axial FOV for 2 to 4 minutes per table position depending on the condition of the patient and scanner performance. All PET images with a 50-cm FOV were reconstructed using an iterative algorithm with CT-derived attenuation correction. Variations in standardized uptake value (SUV) among institutions were minimized using the anthropomorphic body phantom. A calibration factor was analyzed by dividing the actual SUV by the gauged mean SUV in the phantom background to decrease inter-institutional SUV inconsistencies, and the final maxSUV used in this is referred to as revised maxSUV. The adjustment of the inter-institutional variability in SUV narrowed the range from 0.89 to 1.24 to 0.97 to 1.18 when maxSUV ratio was expressed as the maxSUV of each institute for the maxSUV of the control institute (Figure 1).

GTS

FIGURE 2. ROC curves for positive predictive values of pathologic lymph node metastasis, lymphatic invasion, blood vessel invasion, or pleural invasion. ROC curves are for revised maxSUV (A), GGO ratio (B), TDR (C), and BAC ratio (D). *maxSUV*, Maximum standardized uptake value; *GGO*, ground-glass opacity; *TDR*, tumor disappearance rate; *BAC*, bronchioloalveolar carcinoma; *AUC*, area under the curve; *SUV*, standardized uptake value.

Resected tumors were fixed in 10% formalin, embedded in paraffin, and pathologically evaluated (including the largest cut) using hematoxylin–eosin and Elastica van Gieson staining. The amount of bronchioloalveolar carcinoma (BAC) areas proportionate to whole tumors was approximately calculated as the BAC ratio. Independent observers and pathologists blindly evaluated GGO and BAC ratios and TDR, and corrected discrepancies among evaluations using mean values.

Receiver operating characteristic (ROC) curves of the revised maxSUV, GGO ratios, TDR, and BAC ratios to predict lymphatic, blood vessel, and pleural invasion or nodal involvement were generated to determine the cutoff values that yielded optimal sensitivity and specificity. The patient population was subdivided on the basis of the cutoff values of the revised SUVmax, GGO, TDR, and BAC ratios derived from ROC curves. We performed multiple logistic regression analyses to demonstrate independent variables of maxSUV, GGO ratio, TDR, and BAC ratio relative to the prediction of pathologic findings for high malignant grade and recurrence. Survival was calculated using the Kaplan–Meier method, and differences were determined using the log-rank test. Disease-free survival (DFS) was defined as time from date of surgery until the first event (relapse or death from any cause) or last follow-up. Overall survival was defined as time from the date of surgery until death from any cause or last follow-up.

RESULTS

The primary tumor measured by HRCT was 20 mm or less in diameter in 290 patients (58%) and 21 to 30 mm in 212 patients (42%). Lymphatic permeation, blood vessel, and pleural invasion was evident in 76 patients (15%), 92 patients (18%), and 56 patients (11%), respectively, and lymph nodes were involved in 38 (8%) of them.

The ROC curves identified optimal revised maxSUV, GGO, TDR, and BAC ratio cutoff values of 2.5 (area under the curve [AUC], 0.877), 20% (AUC, 0.858), 30% (AUC, 0.870), and 30% (AUC, 0.873), respectively, for predicting pathologic findings of high malignancy (Figure 2). At a cutoff value of 2.5, a high revised maxSUV significantly correlated with male gender, a high CEA value, large tumor, lymphatic invasion, vascular invasion, pleural invasion, and lymph node metastasis (Table 1). Likewise, low TDR, GGO, and BAC ratios were significantly associated with a high CEA value, lymphatic, vascular, pleural invasion, and lymph node metastasis. Possible predictors for lymphatic, vascular, and pleural invasion, and nodal metastasis and recurrence were investigated (Table 2). Revised maxSUV, GGO ratio, TDR, and BAC ratio were all significant determinants for predicting lymphatic permeation, vascular and pleural invasion, nodal metastasis, and recurrence. However, the odds ratios indicated that revised maxSUV and the BAC ratio revealed biological aggressive tumor grade more effectively than GGO ratio and TDR.

A significant difference in DFS was identified (Figure 3) between patients whose adenocarcinoma had revised maxSUV 2.5 or less ($n = 343$; 3-year DFS rate, 96%) and greater than 2.5 ($n = 159$; 3-year DFS rate, 77%; $P < .001$). We also found significant differences in DFS between patients whose adenocarcinoma had GGO ratios of

TABLE 1. Clinical characteristics of patients with cT1N0M0 adenocarcinoma (n = 502)

	Patients (n = 502)	Revised maxSUV		GGO ratio		TDR		BAC ratio	
		≤2.5/>2.5 (n = 343/159)	P value	≥20%/<20% (n = 304/198)	P value	≥30%/<30% (n = 346/156)	P value	≥30%/<30% (n = 304/198)	P value
Age (y) (means ±SD)	65.3 ± 9.6	65.3 ± 9.4/65.5 ± 9.8	.8380	65.0 ± 9.3/65.9 ± 10.0	.2790	64.7 ± 9.4/66.7 ± 9.9	.0365	65.4 ± 9.5/65.3 ± 9.7	.9054
Gender									
Male	223	140/83	.0169	119/104	.0032	144/79	.0597	113/110	<.0001
Female	279	203/76		185/94		202/77		191/88	
CEA (ng/mL)									
≤5	449	321/128	<.0001	289/160	<.0001	324/125	<.0001	284/165	.0003
>5	53	22/31		15/38		22/31		20/33	
Tumor size (mm)									
T ≤20	290	218/72	.0001	183/107	.1723	213/77	.0104	180/110	.4178
<20 T ≤30	212	125/87		121/91		133/79		124/88	
Ly permeation									
positive	76	15/61	<.0001	13/63	<.0001	25/51	<.0001	12/64	<.0001
negative	426	328/98		291/135		321/105		292/134	
V invasion									
positive	92	16/76	<.0001	15/77	<.0001	23/69	<.0001	11/81	<.0001
negative	410	327/83		289/121		323/87		293/117	
P invasion									
positive	56	12/44	<.0001	10/46	<.0001	14/42	<.0001	6/50	<.0001
negative	446	331/115		294/152		332/114		298/148	
N metastasis									
positive	38	10/28	<.0001	8/30	<.0001	10/28	<.0001	5/33	<.0001
negative	464	333/131		296/168		336/128		299/165	

CEA, Carcinoembryonic antigen; Ly, lymphatic; V, blood vessel; P, pleural; N, lymph node; maxSUV, maximum standardized uptake value; GGO, ground-glass opacity; TDR, tumor disappearance rate; BAC, bronchioloalveolar carcinoma.

TABLE 2. Analysis of possible predictors for Ly factor, V factor, P factor, N factor, and recurrence status

Factors total (n = 502)	Favorable	Unfavorable	Odds ratio (95% CI)	P value
Positive Ly factor (n = 76)				
Revised maxSUV	≤2.5	>2.5	13.61 (7.41–25.01)	<.0001
GGO ratio	≥20%	<20%	10.45 (5.56–19.63)	<.0001
TDR	≥30%	<30%	6.24 (3.68–10.56)	<.0001
BAC ratio	≥30%	<30%	11.62 (6.07–22.25)	<.0001
Positive V factor (n = 92)				
Revised maxSUV	≤2.5	>2.5	18.71 (10.37–33.78)	<.0001
GGO ratio	≥20%	<20%	12.26 (6.78–22.17)	<.0001
TDR	≥30%	<30%	11.14 (6.57–18.88)	<.0001
BAC ratio	≥30%	<30%	18.44 (9.48–35.87)	<.0001
Positive P factor (n = 56)				
Revised maxSUV	≤2.5	>2.5	10.55 (5.39–20.68)	<.0001
GGO ratio	≥20%	<20%	8.90 (4.37–18.12)	<.0001
TDR	≥30%	<30%	8.74 (4.60–16.59)	<.0001
BAC ratio	≥30%	<30%	16.78 (7.03–40.03)	<.0001
Positive N factor (n = 38)				
Revised maxSUV	≤2.5	>2.5	7.12 (3.36–15.07)	<.0001
GGO ratio	≥20%	<20%	6.61 (2.96–14.74)	<.0001
TDR	≥30%	<30%	7.35 (3.47–15.56)	<.0001
BAC ratio	≥30%	<30%	11.96 (4.58–31.22)	<.0001
Positive recurrence (n = 29)				
Revised maxSUV	≤2.5	>2.5	7.71 (3.22–18.46)	<.0001
GGO ratio	≥20%	<20%	8.25 (3.09–22.01)	<.0001
TDR	≥30%	<30%	4.66 (2.11–10.28)	<.0001
BAC ratio	≥30%	<30%	10.84 (3.71–31.66)	<.0001

Ly, Lymphatic permeation; V, blood vessel invasion; P, pleural invasion; N, lymph node metastasis; maxSUV, maximum standardized uptake value; GGO, ground-glass opacity; TDR, tumor disappearance rate; BAC, bronchioloalveolar carcinoma.

GTS

FIGURE 3. DFS curves according to grade of revised maxSUV (A), GGO ratio (B), TDR (C), and BAC ratio (D). *maxSUV*, Maximum standardized uptake value; *GGO*, ground-glass opacity; *TDR*, tumor disappearance rate; *BAC*, bronchioloalveolar carcinoma.

20% or more (n = 304; 3-year DFS rate, 97%) and less than 20% (n = 198; 3-year DFS rate, 80%; $P < .001$), between those whose adenocarcinoma had TDR 30% or more (n = 346; 3-year DFS rate, 95%) and less than 30% (n = 156; 3-year DFS rate, 80%; $P < .001$) and between

those whose adenocarcinoma had BAC ratios of 30% or more (n = 304; 3-year DFS rate, 97%) and less than 30% (n = 198; 3-year DFS rate, 80%; $P < .001$). Revised maxSUV ($P = .016$) and GGO ($P = .024$) and pathologic BAC ($P = .005$) ratios were significant prognostic factors

FIGURE 4. Overall survival curves according to grade of revised maxSUV (A), GGO ratio (B), TDR (C), and BAC ratio (D). *maxSUV*, Maximum standardized uptake value; *GGO*, ground-glass opacity; *TDR*, tumor disappearance rate; *BAC*, bronchioloalveolar carcinoma.

TABLE 3. Relationship between ground-glass opacity/tumor disappearance rate and revised maxSUV as predictors for Ly factor, V factor, P factor, N factor, and recurrence status

	Revised maxSUV	Ly permeation (+)/(-)	V invasion (+)/(-)	P invasion (+)/(-)	N metastasis (+)/(-)	Recurrence (+)/(-)
GGO ≤50% and TDR ≤50% (n = 259)	≤1.5 (n = 48)	2/46 (4%)	1/47 (2%)	3/45 (6%)	0/48 (0)	0/48 (0)
	<1.5 ≤2.5 (n = 68)	10/58 (15%)	14/54 (21%)	8/60 (12%)	8/60 (12%)	3/65 (4%)
	2.5< (n = 143)	59/84 (41%)	73/70 (51%)	43/100 (30%)	27/116 (19%)	22/121 (15%)
	>50% GGO or >50% TDR (n = 243)	≤1.5 (n = 180)	2/178 (1%)	1/179 (1%)	0/180 (0)	1/179 (1%)
	<1.5 ≤2.5 (n = 47)	1/46 (2%)	0/47 (0)	1/46 (2%)	1/46 (2%)	2/45 (4%)
	2.5< (n = 16)	2/14 (13%)	3/13 (19%)	1/15 (6%)	1/15 (6%)	0/16 (0)

maxSUV, Maximum standardized uptake value; Ly, lymphatic; V, blood vessel; P, pleural; N, lymph node; GGO, ground-glass opacity; TDR, tumor disappearance rate.

for overall survival, whereas TDR ($P = .056$) was marginally significant (Figure 4).

We examined the relationships between HRCT findings and maxSUV for predicting tumor invasiveness, nodal metastasis, and recurrence (Table 3). Generally, solid tumors on HRCT with GGO 50% or less and TDR 50% or less had high maxSUV and were more frequently associated

with high malignant grade, nodal metastasis, and recurrence. However, solid tumors with lower maxSUV were associated with low malignant grade and far less nodal metastasis and recurrence. Among patients with tumors showing GGO 50% or less and TDR 50% or less, 19% and 15% of those with a revised maxSUV greater than 2.5 had nodal metastasis and recurrence, respectively,

FIGURE 5. Tumor (1.5 cm in diameter) located at right middle lobe. A, HRCT findings show GGO ratio of 5%. B, PET/CT findings show no accumulation. Microscope findings show BAC with mucin formation (C and D, staining with hematoxylin-eosin at ×25 and ×200 magnification, respectively).

FIGURE 6. Relationship between tumor size and revised maxSUV level in cT1N0M0 adenocarcinomas. A, All patients. B, Tumor size ≤ 20 mm and revised maxSUV ≤ 3.0 . Nodal metastasis (*triangles*); recurrence (*rhombi*); lymphatic, vascular, or pleural invasion without nodal metastasis (*squares*). maxSUV, Maximum standardized uptake value; N, lymph node; Ly, lymphatic; V, blood vessel; P, pleural.

whereas those with tumors showing revised maxSUV 1.5 or less had neither nodal metastasis nor recurrence.

DISCUSSION

The frequency of identifying small lung cancers has recently increased since CT and enhanced scanning have become routine procedures and surgeons have thus been able to assess the advantages of sublobar resection, such as radical segmentectomy instead of lobectomy.^{2,3} The biological malignancy of small adenocarcinoma has generally been evaluated on the basis of HRCT findings. The specificity, sensitivity, and accuracy of radiologic

diagnoses with HRCT on lymphatic/vessel invasion and nodal involvement of clinical T1N0M0 adenocarcinoma have been examined in a large prospective study (JCOG0201).¹² The conclusions failed to corroborate predetermined criteria using GGO ratio and TDR for specificity, and thus applicants for radical sublobar resection could not be suitably confirmed on the basis of criteria generated from HRCT findings. Therefore, the development of a novel tool that surpasses the diagnostic ability of HRCT is a current challenge.

Phase III randomized trials of standard lobectomy versus experimental limited resection for small (≤ 2 cm in diameter) peripheral non-small cell lung cancers are ongoing in the United States (CALGB-140503) and in Japan (JCOG0802/WJOG4607L). Because the biological behavior of several types of small lung cancers is aggressive, to detect indolent lung cancers preoperatively with radiographic imaging is important for the standardization of sublobar resection, although accurate radiographic definition of tumor extension and metastasis is challenging. We previously demonstrated that maxSUV on FDG-PET/CT is a potentially promising parameter of the degree of malignancy among cT1N0M0 lung adenocarcinoma.^{7,8} However, relatively few patients were analyzed and postoperative survival data were obtained during a short period. We therefore performed an extended, larger multicenter study. To our knowledge, a large scale multi-institutional study of malignant tumor grade analyzed using PET/CT has not been reported.

The present analyses revealed that adenocarcinoma with high maxSUV and low GGO ratio, TDR, or BAC ratio is more closely associated with lymphatic, vessel, pleural invasion, lymph node metastasis, and recurrence. We also found a closer association between serum CEA levels and maxSUV, GGO ratio, TDR, and BAC ratio, which is preoperatively vital in uncovering patients at high risk of potential advanced disease.^{13,14} High maxSUV was also a poor prognostic determinant for DFS and overall survival. These outcomes suggested that maxSUV can be a realistic surrogate marker of tumor malignancy grade and that FDG-PET/CT in addition to HRCT is a potent prognostic modality with which to detect patients at high risk of recurrence after curative resection of small adenocarcinoma.

Because PET/CT imaging reflects metabolic activity as glucose metabolism whereas HRCT generates only anatomic images, findings of PET/CT could be more powerful clinical predictors of biological tumor performance than those of HRCT. Most solid tumors on HRCT have high maxSUV and aggressive malignant behavior, whereas solid tumors with lower maxSUV were less aggressive. Figure 5 shows a mucinous BAC with indolent behavior that appeared as a solid tumor on HRCT with no accumulation on PET/CT.

We analyzed the association between tumor size and maxSUV in cT1N0M0 adenocarcinoma (Figure 6). A larger

tumor was associated with a higher maximum SUV, and both size and maxSUV can predict tumor invasiveness, nodal metastasis, and recurrence. The figures show a notable tendency of small adenocarcinoma with high maxSUV to have more malignant features than larger adenocarcinoma with low maxSUV.

One of the major limitations of multicenter trials using PET is the wide variation in SUV among institutions. Many factors, such as preparation procedures, scan acquisition, image reconstruction, and data analysis affect SUV,^{15,16} although semiquantitative SUV in patients with cancer is extensively applied to diagnose, stage, and evaluate therapeutic effectiveness.⁴⁻⁶ Westerterp and colleagues¹⁷ reported that a discrepancy in SUV of up to 30% among institutions could create a significant problem for multicenter studies. Inter-institutional variability in SUV obtained in the present study was minimized using an anthropomorphic body phantom. Therefore, quantitative SUVs adjusted by phantom studies can be dependable, and such correction will help to overcome one major limitation of multicenter of PET studies.

CONCLUSIONS

The findings of HRCT and FDG-PET/CT are important to select therapeutic strategies for treating c-stage IA adenocarcinoma of the lung, and maxSUV on FDG-PET/CT is an especially significant preoperative predictor for surgical outcomes. Sublobar resection might be performed in patients with adenocarcinoma with maxSUV 1.5 or less, and lymphadenectomy is required for tumors with maxSUV greater than 1.5.

References

- Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. *Ann Thorac Surg.* 1995;60:615-22.
- Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. *J Thorac Cardiovasc Surg.* 2006;132:769-75.
- Nakayama H, Yamada K, Saito H, Oshita F, Ito H, Kameda Y, et al. Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging. *Ann Thorac Surg.* 2007;84:1675-9.
- Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. *N Engl J Med.* 2000;343:254-61.
- Vansteenkiste J, Fischer BM, Doores C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. *Lancet Oncol.* 2004;5:531-40.
- Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. *N Engl J Med.* 2006;354:496-507.
- Okada M, Tauchi S, Iwanaga K, Mimura T, Kitamura Y, Watanabe H, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. *J Thorac Cardiovasc Surg.* 2007;133:1448-54.
- Nakayama H, Okumura S, Daisaki H, Kato Y, Uehara H, Adachi S, et al. Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: a multicenter study. *Cancer.* 2010;116:3170-7.
- Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. *J Nucl Med.* 2004;45:1734-42.
- Shimizu K, Yamada K, Saito H, Noda K, Nakayama H, Kameda Y, et al. Surgically curable peripheral lung carcinoma. Correlation of thin-section CT findings with histologic prognostic factors and survival. *Chest.* 2005;127:871-8.
- Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. *J Nucl Med.* 2006;47:885-95.
- Suzuki K, Koike T, Shibata T, Kusumoto M, Asamura H, Nagai K, et al. Evaluation of radiologic diagnosis in peripheral clinical IA lung cancers. A prospective study for radiological diagnosis of peripheral early lung cancer (JCOG0201). *J Clin Oncol.* 2006;24:7220.
- Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. *Ann Thorac Surg.* 2004;78:216-21.
- Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. *Ann Thorac Surg.* 2004;78:1004-9.
- Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. *Eur J Nucl Med Mol Imaging.* 2008;35:2320-33.
- Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. *J Nucl Med.* 2004;45:1519-27.
- Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardized uptake values in multicenter trials: effects of image reconstruction, resolution and ROI definition parameters. *Eur J Nucl Med Mol Imaging.* 2007;34:392-404.